Teva Canada and Novartis Canada formed a partnership to ensure continued access to Mayzent (siponimod) for people in Canada living with active secondary progressive multiple sclerosis (SPMS). Teva Canada will take over the promotion, distribution, and commercialization of the oral MS therapy in Canada. The companies say the collaboration is intended to support patients and […]
The post Partners to provide Mayzent access for SPMS patients in Canada appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com